FAQ — Human Longevity EU
In Europe, longevity isn’t only personal—it collides with access, queues, and solidarity.
Is this prescribing or treatment advice?
No—it's context on access and evidence; decisions stay with you and your care system.
Animal vs human data?
We label translational gaps clearly.
Supplements?
We avoid hype lists; mechanisms first.
Updates?
We revise when major evidence shifts.
Biomarkers?
Interesting signals, not destiny—professional interpretation matters.
Anti-ageing guarantees?
None. We discuss evidence limits openly.
Ethics?
Access and equity belong in longevity conversations.